Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 880 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR Addressing Cancer Pain with Complementary Methods (Part 2) April 10, 2023 Is Proton Therapy Safer than Traditional Radiation? February 11, 2020 ‘Levelling Up’: What should it mean for cancer? February 2, 2022 Finding Purpose During Cancer: A Survivor’s Story December 27, 2022 Load more HOT NEWS Coronavirus reports – Part 7: “I’m more concerned about the second... 2023 ASCO Annual Meeting Research Round Up: Advances in Treating Gynecologic... What the Reignited Cancer Moonshot Initiative Means for People With Cancer A Lack of Resistance Gene Alterations in Baseline ctDNA Associated with...
